mTORC1 controls multiple aspects of cell growth and homeostasis, including protein synthesis, lipogenesis, glucose metabolism, autophagy, lysosome biogenesis, proliferation, and survival, in response to environmental cues ranging from levels of amino acids, glucose, energy, and oxygen to growth factors 1-3 . mTOR and other pathway proteins are frequently mutated in cancer, and mTOR inhibitors are approved for the treatment of cancer 4,5 . mTORC1 is an approximately 1-MDa dimeric complex consisting of the phosphoinositide 3 kinase-related protein kinase (PIKK) 6 mTOR, and the subunits RAPTOR and mLST8 (refs 7-10). mTORC1 activation requires nutrients, which are sensed as amino-acid levels and induce mTORC1 recruitment to lysosomal membranes through RAPTOR 2 . There, mTORC1 meets its activator, the small GTPase RHEB, which conveys a second set of signals from environmental cues including energy, oxygen levels, and growth factors 3,11,12 . In metazoans, growth factors also relieve the inhibition of mTORC1 by PRAS40 (refs 13-16).
FRB-S6K1 recruitment peptide structure
To investigate FRB-mediated substrate recruitment 23 by crystallography, we fused a 26-residue S6K1 sequence to the FRB domain owing to the low affinity of this interaction (Michaelis constant (K m ) = 430 μ M, Extended Data Fig. 1a, b ). In the 1.75 Å crystal structure, a 13-residue S6K1 portion adopts an amphipathic helix and packs with the rapamycinbinding site of the FRB ( Fig. 1b and Extended Data Fig. 1e ). Central to the interface is the S6K1 Leu396 side chain that extends from the amphipathic helix and inserts into an FRB pocket (Phe2039, Trp2101, Tyr2105, and Phe2108) where rapamycin inserts a key aliphatic group 25 ( Fig. 1c and Extended Data Fig. 1c ). Additional FRB contacts are made by Val395 and Val399 that flank Leu396.
We confirmed the importance of these interactions by alaninescanning mutagenesis of a 38-residue S6K1 substrate polypeptide (hereafter S6K1 ). The L396A mutation reduced phosphorylation by the truncated mTOR ΔN -mLST8 complex to 3% of the wildtype level, and the other mutations had effects commensurate with either their FRB contacts or helix-stabilizing roles (Fig. 1c, d and Extended Data Fig. 1b ). We also assayed full-length, kinase-inactive S6K1 (hereafter S6K1 ki ) harbouring the L396A mutation and found that its levels of Thr389 phosphorylation by mTORC1 or the truncated mTOR ΔN -mLST8 complex were 53% and 37% of the respective wild-type S6K1 ki reactions, irrespective of the TOS motif (Fig. 1e) . The L396A mutation also reduced Thr389 phosphorylation of S6K1 ki transiently overexpressed in HEK293 cells to 34% of the wild-type level (Fig. 1f) .
The mTORC1 substrates 1,4 GRB10 (refs 19, 26) , TFEB 27 , MAF1 (ref. 28) , and LIPIN 29 also contain hydrophobic amino acids within approximately 15 residues of reported phosphorylation sites (Fig. 1g) .
The mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and metabolism in response to nutrients, energy levels, and growth factors. It contains the atypical kinase mTOR and the RAPTOR subunit that binds to the Tor signalling sequence (TOS) motif of substrates and regulators. mTORC1 is activated by the small GTPase RHEB (Ras homologue enriched in brain) and inhibited by PRAS40. Here we present the 3.0 ångström cryo-electron microscopy structure of mTORC1 and the 3.4 ångström structure of activated RHEB-mTORC1. RHEB binds to mTOR distally from the kinase active site, yet causes a global conformational change that allosterically realigns active-site residues, accelerating catalysis. Cancer-associated hyperactivating mutations map to structural elements that maintain the inactive state, and we provide biochemical evidence that they mimic RHEB relieving auto-inhibition. We also present crystal structures of RAPTOR-TOS motif complexes that define the determinants of TOS recognition, of an mTOR FKBP12-rapamycinbinding (FRB) domain-substrate complex that establishes a second substrate-recruitment mechanism, and of a truncated mTOR-PRAS40 complex that reveals PRAS40 inhibits both substrate-recruitment sites. These findings help explain how mTORC1 selects its substrates, how its kinase activity is controlled, and how it is activated by cancer-associated mutations.
We therefore mutated one or more hydrophobic residues in each substrate in the context of 20-residue synthetic peptides. The mutations reduced phosphorylation of all four substrates by a factor of 4-13, consistent with these substrates using the FRB docking site to enter the catalytic cleft ( Fig. 1g ).
We also investigated 4EBP1, whose Thr37 and Thr46 phosphorylation sites are followed by an amphipathic helix that binds to eIF4E 30 . Appreciable Thr37 phosphorylation required extending the peptide to the first turn of the amphipathic helix, which when mutated reduced phosphorylation back to a barely detectable level ( Fig. 1g ). With the Thr46 site, the 20-residue peptide that reaches partway to the amphipathic helix was phosphorylated approximately fivefold less than a peptide encompassing the entire helix. In this longer peptide, mutation of the first and second sets of hydrophobic residues reduced phosphory lation by a factor of approximately 8 and 3, respectively ( Fig. 1g ). Consistent with the amphipathic helix being recruited by the FRB, addition of eIF4E, which sequesters the helix, reduced full-length 4EBP1 phosphorylation by both mTORC1 and mTOR ΔN -mLST8 by a factor of approximately 4 ( Fig. 1h and Extended Data Fig. 1d ).
Crystal structures of Raptor-TOS motif complexes
We determined the crystal structures of Arabidopsis thaliana Raptor (atRaptor) bound to TOS motif peptides from human 4EBP1, S6K1, and PRAS40, at 3.0, 3.1, and 3.35 Å resolution, respectively, and apo-atRaptor at 3.0 Å ( Fig. 2a and Extended Data Table 1 ). The atRaptor residues that contact the TOS peptides are identical in human RAPTOR, and the atRaptor-4EBP1 TOS interface (Fig. 2b) does not differ discernibly in the 3.0 Å human mTORC1-4EBP1 cryo-EM structure described below (Extended Data Fig. 2 ).
RAPTOR has a sausage-like shape, with the N-terminal caspasehomology domain 31 at one end, an α − α solenoid of approximately eight armadillo repeats in the middle, and a C-terminal WD40 domain at the other end ( Fig. 2a) . The caspase-homology domain can be superimposed on caspase6 with a root-mean square deviation of approximately 3 Å for 175 C α atoms, although RAPTOR lacks the caspase Cys-His catalytic dyad 31 (Supplementary Discussion). The TOS peptides bind to a groove between the caspase fold and the solenoid, approximately 65 Å away from the kinase active site ( Fig. 1a ). One side of this groove is formed by a four-helix insertion in the caspase fold, and the other side by the first three armadillo repeats ( Fig. 2a ).
All three TOS peptides have an equivalent eight-residue segment ordered in the crystals (Extended Data Fig. 3a-d ). The key phenylalanine side chain of the TOS consensus 21, 22 FXΦ DΦ (Φ hydrophobic, X any residue) binds to a pocket together with the preceding TOS residue (hereafter F −1 position). In 4EBP1, this unit consists of the Phe114 aromatic ring making π − π stacking interactions with the Gln113 side chain, whereas in S6K1 and PRAS40 the Phe5 and Phe129 aromatic rings make functionally analogous van der Waals contacts with Val4 and Leu128, respectively ( Fig. 2b-d ). In addition, the phenylalanine backbone amide group hydrogen bonds to Tyr475 (human RAPTOR numbering). Alanine mutation of the 4EBP1 Gln113 reduces its affinity for human RAPTOR by a factor of 20, confirming the importance of its stacking with the phenylalanine and recognition of the residue pair as a unit (dissociation constant (K d ) values in Extended Data Fig. 3e , f).
The other conserved TOS residues make overall conserved RAPTOR contacts ( Fig. 2b-d ). The hydrophobic F +2 side chain (Met116, Ile7, and Met131 of 4EBP1, S6K1, and PRAS40, respectively) binds into a tight pocket at the bottom of the groove, and accordingly its alanine mutation reduces binding by nearly two orders of magnitude (Extended Data Fig. 3e ). The F +3 aspartic acid side chain forms a hydrogen bond network involving Arg305 and the F +1 backbone carbonyl group, and its mutation increases the K d fivefold (Extended Data Fig. 3d, e ). By contrast, the hydrophobic F +4 side chain (4EBP1 Ile118 and S6K1 Leu9; PRAS40 Glu133 is disordered) binds to a shallow, solvent-exposed surface pocket, and its mutation reduces binding only modestly (Extended Data Fig. 3e ).
Consistent with the conservation of contacts in the three structures, the PRAS40 inhibitor has a TOS-RAPTOR K d similar to those of S6K1 f, Phosphorylation of wild-type and mutant HA-S6K1 ki in HEK293 cells (asterisk, endogenous S6K1). e, f, Products detected by pT389-specific antibody and plotted relative to the wild-type reaction of each series (means as columns, four independent experiments with markers). g, Phosphorylation of indicated wild-type and mutant (red mutation) peptides (10 μ M) of indicated substrates, plotted as bars for means and markers for independent experiments (4EBP1, n = 3; rest, n = 4). 4EBP1 amphipathic helix underlined; asterisk, phosphorylation sites; grey, alanine-mutated second phosphorylation sites. h, Phosphorylation of indicated 4EBP1 concentrations by 30 nM mTOR ΔN -mLST8 or mTORC1 in the presence of one molar equivalent eIF4E or GST control (plotted in Extended Data Fig. 1d ).
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and 4EBP1 (Extended Data Fig. 3f ). This suggested that PRAS40 has additional mTORC1-interacting elements.
PRAS40 blocks the FRB substrate-recruitment site
To identify additional mTORC1-binding elements of PRAS40, we first tested whether the PRAS40 segment reported to be necessary for inhibition ) can also inhibit mTOR ΔN -mLST8phosphory lating S6K1 367-404 . PRAS40 114-256 inhibited this TOSindependent reaction with an apparent inhibitor constant (K i ) of approximately 52 μ M (calculated from half-maximum inhibitory concentration (IC 50 ) values; Fig. 3a ), which is significantly lower than the approximately 430 μ M K m of S6K1 367-404 (Extended Data Fig. 1b ). As expected, deletion of TOS (PRAS40 173-256 ) had no effect, but deletion of 33 additional residues (PRAS40 206-256 ) reduced inhibition by a factor of approximately 4 ( Fig. 3a ). Very similar results were obtained with the 4EBP1 42-64 substrate (Extended Data Fig. 4a ).
We next determined the 3.4 Å co-crystal structure of PRAS40 173-256 bound to mTOR ΔN -mLST8 (Extended Data Fig. 4f ). The structure revealed two PRAS40 anchor points separated by an unstructured segment: an amphipathic α -helix (residues 212-232) bound to the FRB domain and a β -strand (residues 188-196) bound to the mLST8 WD40 domain ( Fig. 1a and Extended Data Fig. 4b ).
The amphipathic helix binds to the same FRB site as the S6K1 substrate, but at five turns it is substantially longer and makes more extensive contacts than S6K1 (Fig. 3b , c and Extended Data Fig. 4c ). PRAS40 uses the Met222 side chain to bind to the same rapamycinbinding pocket as the S6K1 Leu396 (Fig. 3c ), and five additional hydrophobic side chains (Leu215, Ile 218, Ala219, Leu225, and Val 226) to contact an extended FRB surface.
The PRAS40 β -strand has a phenylalanine side chain (Phe193) inserting into a pocket between two mLST8 β -propeller blades (Tyr195, Trp197, Pro167, Pro212), and its peptide backbone makes three β -sheet hydrogen bonds to the edge of one β -propeller ( Fig. 3d and Extended Data Fig. 4d ). These PRAS40 interactions are consistent with reduced inhibition by PRAS40 206-256 , which lacks the β -strand, compared with PRAS40 173-256 ( Fig. 3a) .
We further confirmed the importance of the amphipathic helix by mutating Met222 and four additional FRB-interacting residues (L215A, I218A, A219G, L225A) in full-length PRAS40. As shown in Fig. 3e , the mutations reduced inhibition of mTORC1 phosphorylating full-length 4EBP1 by a factor of approximately 50.
mTORC1 and RHEB-mTORC1 cryo-EM structures
To address how RHEB activates mTORC1, we collected cryo-EM data on mTORC1 that was crosslinked in the presence of excess RHEB-GTPγ S and 4EBP1 (Extended Data Fig. 2c ). The 3D auto-refinement of 580,768 particles in C 2 symmetry led to a consensus reconstruction extending to 3.2 Å resolution, as determined by the gold-standard Fourier shell correlation (FSC) procedure 32 (Extended Data Fig. 5a, b ). In subsequent 3D classification in C 1 , most classes appeared to belong to a continuum of conformational states. One class with approximately 20% of the particles had an overall conformation distinct from the ensemble of the other classes, and this was the only class that contained RHEB, one on each mTOR of dimeric mTORC1 (Extended Data Fig. 5c-e ).
Because of the conformational flexibility between and within the two mTOR-RAPTOR-mLST8 complexes (Extended Data Fig. 5c ), we converted the particles to monomers with partial signal subtraction 33 , and calculated focused reconstructions with three partly overlapping masks (2.98, 2.95, and 2.96 Å; Extended Data Fig. 5a , b). Using these three As with the mTOR ΔN -mLST8 crystal structure 23 , the PIKK-specific FAT domain adopts a C-shaped solenoid structure that clamps onto the kinase domain, with the start of the solenoid interacting with the kinase domain N-lobe, and its end with both the N-and C-lobes ( Fig. 4a ). In keeping with the secondary structures of previous mTOR cryo-EM reconstructions 24, 35 , the N-terminal segment missing from mTOR ΔN starts with an α − α solenoid of 18 HEAT repeats (N-heat), followed by a smaller middle solenoid of 7.5 HEAT repeats (M-heat), and an approximately 110 residue helical-repeat segment that is structurally contiguous with the subsequent FAT domain and is henceforth included in the 'FAT' descriptor (Extended Data Figs 6 and 7b, c). The FAT solenoid acts as an organizing centre of mTOR. In addition to its ends clamping onto the kinase domain N-and C-lobes, the FAT mid-portion packs with the N-heat solenoid end, and the beginning of the FAT packs with the start of the M-heat solenoid, anchoring the two domains ( Fig. 4a , Extended Data Figs 6 and 7d and Supplementary Discussion).
The mTORC1 dimer forms through the C-terminal portion of N-heat packing with the M-heat of the second protomer in a reciprocal fashion (Fig. 4b ). RAPTOR binds to this interface as well, resulting in a tripartite interface of 5,420 Å 2 buried surface area, of which 38% is from RAPTOR-N-heat, 23% from RAPTOR-M-heat, and 39% from N-heat-M-heat (Extended Data Fig. 7e , f). RHEB binds to the N-terminal portions of the N-heat, M-heat, and FAT domains, forming a four-way interface (Fig. 4a, c) . Most of the contacts are made by the RHEB switch I and switch II regions, which have GTP-dependent conformations as with other small GTPases 36 . Switch I (residues 33-41) binds to M-heat and FAT, whereas the longer switch II (residues 63-79) interacts with all three mTOR regions ( Fig. 4c and Extended Data Fig. 8a ).
RHEB allosterically activates mTORC1
In apo-mTORC1, the N-heat RHEB-binding site is far away from those on M-heat and FAT, displaced by approximately 18 Å relative to its position in the RHEB-bound state (Fig. 5a ). On RHEB binding, the N-heat solenoid swings in towards M-heat through an approximately 19° rotation, reconstituting the RHEB-binding site and inducing new interactions between the N-terminal portions of N-heat and FAT (Figs 4c and 5a and Supplementary Video 1). This causes a conformational change within the FAT domain, whose middle portion gets twisted and dragged by the moving N-heat solenoid end that is anchored on it. The intra-FAT conformational change is entirely distinct from the conformational flexibility apo-mTORC1 exhibits (Extended Data Fig. 7f and Supplementary Discussion). The two conformations are incompatible in a mixed dimer, as this would require a greater than 20 Å offset in the N-heat portion of the dimerization interface. This explains the lack of single-RHEB 3D classes, and suggests that two RHEB molecules bind to mTORC1 cooperatively. In support of this, we find that the RHEB-GTPγ S response curve of mTORC1 phosphorylating 4EBP1 best fits a Hill slope model with a Hill coefficient of approximately 2.0 ( Fig. 5b ; the approximately 100 μ M half-maximum effective concentration (EC 50 ) in solution is probably not reflective of the membrane-surface reaction in vivo 2, 36 ).
The intra-FAT conformational change occurs at hinge regions that allow for relative rotations of flanking segments. One hinge around residue 1443 is associated with a major rotation of 30° between the FAT sub-domains TRD1 and TRD2 (ref. 23) , and two other hinges exhibit smaller rotations ( Fig. 5c ). These conformational changes in the FAT are coupled to its C-terminal portion moving away from the kinase, the N-lobe of the kinase moving in to the space vacated by the FAT, the FAT-N-lobe interface repacking into a looser arrangement, and the catalytic cleft between the N-and C-lobes closing by 8° ( Fig. 5c, d and Supplementary Video 2).
The closing of the catalytic cleft changes the relative orientation of the ATP-contacting and catalytic residues from the N-and C-lobes. This brings the ATP phosphate groups that are bound by the N-lobe into closer proximity with critical C-lobe residues that include the Mg 2+ ligands 23 (Asn2343 and Asp2357) and the two catalytic residues 23 (Asp2338 and His2340) ( Fig. 5e , f and Extended Data Fig. 8b, c) .
This indicates that RHEB activates mTORC1 by allosterically realigning active-site residues, bringing them into the correct register for catalysis. To confirm this, we compared the steady-state kinetic constants of S6K1 367-404 phosphorylation by mTORC1 in the presence of 250 μ M RHEB-GTPγ S or RHEB-GDP. Activation is accounted for entirely by an approximately 30-fold increase in the catalytic constant (k cat ), from 0.09 s −1 to 2.9 s −1 , whereas K m values remain essentially unchanged ( Fig. 5g) . RHEB similarly increased the apparent k cat of fulllength 4EBP1 phosphorylation, including under single-turnover conditions, the latter indicating that the k cat effect involves the catalytic step and not a hypothetically rate-limiting product-release step (Extended Data Fig. 8d, e ). RHEB-GTPγ S also accelerated idle ATP hydrolysis, a low-level activity common in protein kinases as well as PI3K 37 (Extended Data Fig. 8f ).
Cancer-associated hyperactive mTOR mutants
Cancer-associated hyperactivating mutations 5,38-40 predominantly involve structure-stabilizing residues. They cluster at the major intra-FAT hinge, the FAT-N-lobe packing transition, and the N-lobe anchor in a pocket between the C-lobe and FAT, suggesting that they act by lowering the barriers to the N-lobe adopting the active conformation, mimicking the effects of RHEB ( Fig. 6a and Extended Data Fig. 9a-c) .
This hypothesis predicts that the mutations should lower the EC 50 of activation by RHEB, as part of the RHEB-mTORC1 binding energy must be used to affect the conformational change, and that they should not synergize with saturating RHEB. To test these predictions, we transiently expressed and purified four representative hyperactive mTORC1 mutants 5,38 : A1459P in the middle of a helix at the major intra-FAT hinge, T1977R buried at the FAT-N-lobe transition, and S2215Y and E2419K at the N-lobe-C-lobe and juxtaposed C-lobe-FAT interfaces, respectively ( Fig. 6a and Extended Data Fig. 9a-c) .
After confirming that the mutations increase the k cat of mTORC1 phosphorylating S6K1 367-404 without affecting the K m (Extended Data Fig. 9d ), we assessed their RHEB-GTPγ S dose-response curves. All four mutations shifted the response curve to lower RHEB concentrations compared with wild-type mTORC1, produced as the mutants (Fig. 6b ). A1459P, S2215Y, and E2419K reduced the EC 50 comparably, by factors of 6.6, 7.0, and 7.4, respectively, whereas T1977R reduced it by a factor of 4.0 ( Fig. 6b) . Importantly, the mutations did not synergize with RHEB, as at the highest, nearly saturating RHEB concentration, the mutants exhibited S6K1 367-404 phosphorylation levels within approximately 15% of the wild-type control (reaction velocity/enzyme concentration, v/[E], of 3.7 s −1 for wild-type, and 4.1-4.4 s −1 for the mutants; Fig. 6b ).
The mutations also reduced the cooperativity of RHEB binding, suggesting they enable the formation of single-RHEB-containing mTORC1 (Fig. 6b ). We presume this is due to the destabilization of the inhibitory FAT clamp, either directly or indirectly at its anchors on the N-and C-lobes, enabling the FAT-bound N-heat to reach the tripartite dimerization interface of a mixed dimer.
Conclusion
We show that the TOS motif docking site is approximately 65 Å from the kinase active site, suggesting that it acts to increase the effective substrate concentration, and we establish a second substrate-docking site corresponding to the rapamycin-binding site at the entrance of the catalytic cleft. PRAS40 binds to both substrate-docking sites and an additional site on mLST8 to achieve inhibition. We also show that the low kinase activity of apo-mTORC1 is due to a misalignment of the kinase N-and C-lobes and their associated ATP-binding and catalytic residues. The FAT clamp, present in all PIKKs, is a key autoinhibitory element that keeps the N-lobe misaligned. RHEB, binding approximately 60 Å away from the active site, induces a movement of the N-heat domain, which pulls and twists the FAT clamp, freeing the N-lobe to adopt the active conformation. The end result of this process is probably mimicked by cancer-associated mutations that activate mTOR.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Fig. 4a (thick red sticks, mutated residues; assayed mutants labelled). b, RHEB-GTPγ S activating S6K1 367-404 (150 μ M) phosphorylation by wild-type or indicated mutant mTORC1 (10 nM). Plotted with means as dashes and individual values from three independent experiments with indicated markers and colours. Dose-response curves and coefficients also shown.
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MethODS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Protein expression and purification. For the FRB-S6K1 389-414 fusion protein, a synthetic gene encoding the FRB domain of human mTOR (residues 2018-2114) followed by a three-amino-acid linker (SGG) and residues 389-414 of human S6K1α II was cloned into a modified pGEX4T3 vector. The fusion protein was overexpressed in the Escherichia coli strain BL21(DE3), and was purified by glutathione-affinity chromatography, removal of the GST tag with TEV protease, and fractionation by ion exchange and size-exclusion chromatography. The peak fractions were concentrated to 40 mg ml −1 in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 10% glycerol and 0.5 mM tris-(2-carboxyethyl) phosphine (TCEP).
Human S6K1 367-404 wild-type and mutant peptides were produced in E. coli as GST-tag proteins using a modified pGEX4T3 vector. Following glutathione-affinity chromatography and on-bead cleavage with GST-TEV protease, the recombinant peptides were purified by reversed-phase high-performance liquid chromatography using a Zorbax 300SB-C3 column (Agilent). All other peptides used for kinase assays were purchased from Bio-Synthesis or Peptide 2.0 and further purified on high-performance liquid chromatography using Zorbax 300SB-C3 or C18 columns when necessary. Molecular masses for all purified peptides were verified using matrixassisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. Peptides used in crystallization experiments were purchased from Peptide 2.0.
4EBP1 and S6K1 ki and their mutants were prepared as previously described 23 . For the TOS-mutated S6K1 ki, TOS-, residues 5-9 (FDIDL) were mutated to alanines; and for 4EBP1 TOS-, residues 114-118 (FEMDI) were mutated to alanines.
Human eIF4E was produced by infecting High Five insect cells with a pFastBac1 baculovirus expressing the GST-tagged protein and purified similarly as described above, except that 0.1 mM 7-methyl-GDP (Sigma) was added to the elution buffer during the glutathione-affinity chromatography.
PRAS40 fragments were overexpressed and purified as with the FRB-S6K1 389-414 fusion protein. For SeMet-substituted PRAS40 fragments, E. coli transformants were cultured in LB medium at 37 °C until the absorbance at 600 nm reached 0.8; they were then pelleted, washed, and resuspended in M9 medium containing 50 mg l −1 Leu/Ile/Val, 100 mg l −1 Phe/Lys/Thr, and 90 mg l −1 SeMet. The culture was incubated for 30 min to shut down methionine biosynthesis. Protein expression was induced with 1 mM isopropyl β -d-1-thiogalactopyranoside (IPTG) for 3 h at 37 °C.
Full-length human PRAS40 (PRAS40 WT ) was produced by infecting High Five insect cells with pFastBac1 baculovirus expressing the GST-tagged fusion protein. It was purified by glutathione-affinity chromatography, removal of the GST tag with TEV protease, and by anion exchange and size-exclusion chromatography. The peak fraction was concentrated to approximately 1 mM in 20 mM Tris-HCl, pH 8.0, 400 mM NaCl, 10% glycerol, and 10 mM dithiothreitol. PRAS40 α-mut containing five mutations on its FRB-binding α -helix (L215A, I218A, A219G, M222A, and L225A, generated by a QuikChange Lightning Multi Site-Directed Mutagenesis kit, Agilent Technologies) was produced similarly.
A. thaliana Raptor (Genebank Q93YQ1) containing an internal deletion (residues 883-942) was produced by infecting High Five insect cells with a pFastBac1 baculovirus expressing the GST-tagged protein. It was purified by glutathione-affinity chromatography, removal of the GST tag with TEV protease, and by ion exchange and size-exclusion chromatography. The peak fraction was concentrated to 7-9 mg ml −1 in 20 mM Tris-HCl, pH 8.0, 400 mM NaCl, 5% glycerol, 0.5 mM TCEP.
The mTORC1 complex and mTOR ΔN -mLST8 complex were prepared from stably transfected cell as previously described 23 . The cancer-derived mTORC1 mutants and the matched wild-type control were produced by transient transfection. Flag-tagged human mTOR wild type and four cancer-derived hyperactivating mutants, A1459P, T1977R, S2215Y, and E2419K (generated with a QuikChange Lightning Site-Directed Mutagenesis kit, Agilent Technologies), were cloned into the pcDNA3.1(+ ) vector. The corresponding mTOR plasmids (40 μ g per 15 cm plate) were co-transfected with the pcDNA3.1(+ )-human mLST8 plasmid (5 μ g per 15 cm plate) using Lipofectamine 2000 into a HEK293F cell line stably overexpressing the Flag-tagged human RAPTOR. After incubation for 2 days, approximately 60 plates of cells per complex were collected by gentle scraping and lysed in 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% (v/v) glycerol, 2 mM dithiothreitol, and protease inhibitors using French Press. After lysate clarification, the Flag-tagged proteins were isolated using anti-Flag M2 agarose beads (Sigma), extensively washed with lysis buffer supplemented with 200 mM Li 2 SO 4 , and eluted with 0.2 mg ml −1 Flag peptide in lysis buffer. They were then further purified by anion exchange chromatography (MonoQ). Peak fractions containing the wild-type or mutant mTORC1 complexes were then concentrated to approximately 1 mg ml −1 (~ 2 μ M) and stored in small aliquots in − 80 °C.
To prepare nucleotide-bound RHEB, RHEB was overexpressed and purified similarly as FRB-S6K1 389-414 fusion protein. To charge RHEB with GDP, the protein was first dialysed overnight against a buffer containing 20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 5% glycerol, 5 mM EDTA, 0.5 mM TCEP, and 100 mg l −1 acid-washed activated charcoal (Sigma). Next, the protein was incubated with 30-fold molar excess of GDP (Sigma-Aldrich) on ice for 30 min followed by addition of 15 mM MgCl 2 . To charge RHEB with GTPγ S, the protein was incubated with 30-fold molar excess of GTPγ S (Sigma), 20 mM EDTA, and 10 units of alkaline phosphatase (New England BioLabs) per milligram of RHEB at 30 °C for 1 h followed by addition of 40 mM MgCl 2 . Both states of charged RHEB were then purified by size-exclusion chromatography (Superdex 75) in 20 mM bicine, pH 8.0, 200 mM NaCl, 5% glycerol, 5 mM MgCl 2 , and 0.1 mM TCEP. The peak fractions were concentrated to 25-40 mg ml −1 . Crystallization and X-ray data collection. FRB-S6K1 389-414 crystals were grown by the hanging-drop vapour diffusion method at 16 °C from 100 mM bis-tris propane, pH 7.0, 30% Tacsimate (Hampton Research). Crystals were transferred to 100 mM bis-tris propane, pH 7.0, 6.3 M NaFormate and flash-frozen in liquid nitrogen.
AtRaptor native crystals were grown at 4 °C by the hanging-drop vapour diffusion method from a crystallization buffer of 100 mM HEPES, pH 7.5, 50 mM Ca(OAc) 2 , 4-8% PEG 8000, 0.5 mM TCEP. For heavy-atom derivatives, crystals were soaked in 0.4-0.8 mM thimerosal for 2 h before cryo-protection (not shown). The atRaptor-TOS complexes were grown by streak-seeding native crystals into atRaptor mixed with a twofold molar excess of synthetic TOS peptides corresponding to residues 99-118 of human 4EBP1 (RNSPEDKRAGGEESQFEMDI; only underlined residues were ordered in the crystals), residues 1-14 of human S6K1 (MAGVFDIDLDQPED), and residues 124-139 of human PRAS40 (DNGGLFVMDEDATLQD). Crystals were cryo-protected in crystallization buffer supplemented with 20% PEG 400 and flash-frozen in liquid nitrogen.
For the initial PRAS40-mTOR ΔN -mLST8-and SeMet-PRAS40-containing complex, 30 μ M mTOR ΔN -mLST8 was incubated with 0.2 mM of truncated PRAS40, followed by crystallization by the hanging-drop vapour diffusion method. Co-crystals of the complex grew in the same condition as the apo-mTOR ΔN -mLST8 crystals 23 , and subsequent PRAS40 crystals were prepared by soaking apo-mTOR ΔN -mLST8 crystals with 0.5 mM PRAS40 fragments. Crystals were cryo-protected as described 23 .
All diffraction data were collected at − 170 °C at the ID24C or ID24E beamlines of the Advanced Photon Source. Crystals containing SeMet were collected at the Se edge using the inverse beam strategy. Data were processed with the HKL suite 41 . Crystal structure determination and refinement. For the FRB-S6K1 structure, initial phases were obtained by molecular replacement with PHASER 42 using the FRB structure (Protein Data Bank accession number 1FAP) as the search model. The FRB-S6K1 and other crystal structures described in this study were built using O 43 and refined with REFMAC5 (ref. 42 ) and PHENIX 44 . The FRB-S6K1 model has a Molprobity clashscore of 0.36. The Ramachandran plot has 99.8, 0.2, and 0% of the residues in the favoured, allowed, and outlier regions, respectively.
For atRaptor, initial phases were calculated from two thimerosal derivatives using both isomorphous and dispersive differences. The atRaptor used in crystallization has an internal deletion of residues 883-942, a region that is highly susceptible to proteolysis. In the crystals the residues 866-882 and 943-956 flanking the internal deletion, and residues 736-830, are disordered. The corresponding regions are also disordered in the 3.0 Å-refined human RAPTOR structure from our cryo-EM reconstruction. The atRaptor model has a Molprobity clashscore of 4.77. The Ramachandran plot has 89.66, 7.75 and 2.59% of the residues in the favoured, allowed, and outlier regions, respectively.
The PRAS40-mTOR ΔN -mLST8 crystal structures were solved by molecular replacement using the mTOR ΔN -mLST8 structure 23 as a search model. The model has a Molprobity clashscore of 1.92, and the Ramachandran plot has 93.74, 5.3 and 0.95% of the residues in the favoured, allowed, and outlier regions, respectively. Cryo-EM sample preparation and data collection. Cryo-EM samples were prepared using two different crosslinking procedures. In the initial, high-salt crosslinking procedure, 0.42 μ M mTORC1 was incubated with 250 μ M RHEB-GTPγ S, 10 μ M 4EBP1, 0.2 mM GTPγ S, 1 mM AMP-PNP for 10 min, and crosslinked with 0.18% (v/v) glutaraldehyde for 45 min on ice in 20 mM bicine, pH 8.0, 300 mM NaCl, 10% glycerol, 5 mM MgCl 2 , and 0.5 mM TCEP. The reaction was quenched with 100 mM Tris-HCl, pH 8.0, and the mixture was purified by size-exclusion chromatography (Superose 6) in 20 mM Tris-HCl, pH 8.0, 260 mM NaCl, 5 mM MgCl 2 , and 0.1 mM TCEP. Peak fractions were concentrated by ultrafiltration to 1 mg ml −1 and were supplemented with 100 μ M RHEB-GTPγ S, 10 μ M 4EBP1, 0.2 mM GTPγ S, and 1 mM AMPPNP. The sample (3 μ l) was applied to glow-discharged UltrAuFoil 300 mesh R1.2/1.3 grids (Quantifoil). Grids were blotted for 2.5 s at 22 °C and approximately 95% humidity and plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV.
After determining that high ionic strength severely reduced RHEB activation (not shown), we reduced the salt concentration and modified the crosslinking procedure by first reducing the concentrations of mTORC1, RHEB-GTPγ S, and NaCl to 0.21 μ M, 120 μ M, and 100 mM, respectively, then crosslinking with 0.24 mM BS3 for 45 min on ice, followed by the addition of 130 μ M RHEB and 160 mM NaCl and further crosslinking with 0.18% of glutaraldehyde for 45 min. Quenching and purification were performed as with the high-salt procedure in 260 mM NaCl. The main dataset used for apo-mTORC1 reconstruction was collected at the New York Structural Biology Center Simons Electron Microscopy Center using LEGINON 45 . All reported resolutions are from gold-standard refinement procedures with the FSC = 0.143 criterion 32 after post-processing by applying a soft mask, correction for the modulation transfer function of the detector, temperature-factor sharpening, and correction of FSC curves to account for the effects of the soft mask as implemented in RELION 48, 49 . Initial references for template-based particle picking were from 2D-class averages of manually picked particles. Multiple rounds of 2D and, for some data subsets, 3D classifications were then used to remove false positives and particles that clustered in classes with poorly determined orientations. For the main dataset, a total of 580,768 particles were retained (Extended Data Fig. 5a ). After an initial 3D auto-refinement with C 2 symmetry, the particles were improved by particle-based motion correction and radiation-damage weighting 50 . The resulting 'polished' particles were used for the 3D auto-refinement of a consensus mTORC1 dimer map in C 2 , yielding a 3.23Å reconstruction (Extended Data Fig. 5a ). After 3D classification in point group C 1 , 114,879 (19.7%) of the polished particles clustered to a single RHEB-containing class. The fraction of RHEB-containing particles was approximately 2.5-fold higher in the low-salt crosslinked particles than the high-salt ones. The remaining six apo-mTORC1 3D classes appeared to sample a continuum of conformational flexibility, both between and within the two mTOR-RAPTOR-mLST8 complexes (Extended Data Fig. 5a ). Because of this conformational flexibility, we converted the particles to a 'monomeric' form (illustrated in Extended Data Fig. 5a ). For this, we duplicated the particle list and advanced the RELION rot angle by 180° to extract the signal of the second copy of the complex superimposed on the first. We then subtracted the signal from the masked map of the second mTOR-RAPTOR-mLST8 complex in the consensus reconstruction (before post-processing) from each particle in the combined set as described 33 . Three-dimensional auto-refinement then yielded a monomeric mTORC1 consensus reconstruction to 3.11 Å. An alternative, 'pseudo-monomer' set of particles was calculated by switching the two N-heat domains, as this domain seemed to move more relative to its own mTOR than to that of the second protomer. Threedimensional auto-refinement of the 'pseudo-monomer' yielded a reconstruction to 3.02 Å. Upon further inspection of the modes of flexibility in 3D classification of the 'monomeric' complexes, three partly overlapping soft masks were constructed for masked 3D auto-refinements with local searches of orientation angles. One focused on N-heat (17-903), FAT-kinase-domain (1261-2549), the kinasedomain-proximal M-heat portion (933-1005), and mLST8 of the actual monomer (mask 1 in Extended Data Fig. 5a ), and produced a reconstruction to 2.98 Å. The second used the pseudo-monomer focusing on N-heat of protomer 2, RAPTOR, and the RAPTOR-proximal M-heat portion of protomer 1 (1006-1222), and produced a reconstruction to 2.95 Å (mask 2 in Extended Data Fig. 5a ). The third also used the pseudo-monomer, focusing on N-heat, a smaller portion of the proximal M-heat (1027-1222), and nearby segments of RAPTOR (195-214, 237-255, 274-503), to 2.96 Å (mask 3 in Extended Data Fig. 5a ). This third reconstruction had the best density for N-heat. The same procedure of particle duplication and signal subtraction was used to convert the 114,879 RHEB-mTORC1 particles to monomer and pseudo-monomer forms (Extended Data Fig. 5a ). These two sets of particles were combined with the RHEB-containing monomer and pseudo-monomer particles of the second dataset that were processed similarly and which were down-scaled in Fourier space with RELION to match the magnification of the first dataset. The optimal scale factor was determined by comparing the kinase domain C-lobe portion of the refined structures from the two datasets to the crystal structure of mTOR ΔN -mLST8, minimizing the sum of differences squared in the inter-C α distances. The combined total of 396,474 RHEBcontaining particle sets was then 3D auto-refined as with the consensus structure, except for the inclusion of RHEB bound to M-heat mask 1, and in masks 2 and 3 the inclusion of RHEB and the minimal RHEB-interacting M-heat and FAT elements of protomer 2. The dimeric mTORC1-RHEB reconstruction was to 3.8 Å, the monomers to 3.58 Å, and the three focused 3D refinements to 3.43, 3.41, and 3.38Å (Extended Data Fig. 5a ). The inclusion of the down-scaled particles from the second dataset improved the resolution limits only marginally, but the maps had better continuity, especially in the relatively less ordered regions. Cryo-EM structure refinement. Model refinement was done with REFMAC5 modified for cryo-EM 34 , with a composite map of the three focused 3D reconstructions assigned to the following coordinates: N-heat, and for RHEB-mTORC1, RHEB-GTPγ S, and minimal RHEB-interacting M-heat and FAT portions (both duplicated) to the third focused map; M-heat (961-1222), RAPTOR, TOS, and RAPTOR-bound β -strand from M-heat-FAT linker to the second focused map; M-heat (933-960), FAT-kinase-domain (1261-2549), AMPPNP, mLST8, and for RHEB-mTORC1, RHEB-GTPγ S, and minimal RHEB-interacting regions of N-heat (duplicated) of protomer 2 to the third focused map. The three focused maps were aligned on the corresponding regions of the consensus C 2 map by first obtaining the rotation-translation matrix with CHIMERA 51 and then applying the transformation with CCP4 (ref. 42) . The resulting composite maps were used for building a model of the monomeric complex using O 43 , and for refinement with REFMAC5 (ref. 42 ) and PHENIX 44 . The apo-mTORC1 monomer was refined to 3.0 Å with weak secondary structure restraints generated by ProSMART 52 , and the RHEB-mTORC1 monomer to 3.4 Å with tighter secondary structure restraints. RHEB was built on the basis of the published structure 36 . Validation refinement was done as described 34 . To refine the dimeric complexes, two copies of the three focused maps of each complex were aligned on the corresponding C 2 maps as above. The six resulting maps for each complex were then combined with the composite sfcalc option of REFMAC5 to construct the high-resolution structure factors as described for the monomers. The dimeric apo-mTORC1 and RHEB-mTORC1 models were refined against these structure factors using tight non-crystallographic symmetry restraints for the positions and B-factors of the atoms. In vitro kinase assays. In vitro kinase assays were performed as described 23 , except reaction duration was 20 min. In brief, reactants were assembled in a buffer of 25 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 2 mM dithiothreitol, 5% (v/v) glycerol and allowed to incubate on ice for 5 min. Reactions were started by the addition of cold ATP (0.5 mM final concentration except for Extended Data Fig. 8f , which were added at the indicated concentrations) supplemented with 2-4 μ Ci [γ -32 P]ATP (6,000 Ci mmol −1 , Perkin-Elmer) per reaction. Reactions with RHEB-GTPγ S or RHEB-GDP were supplemented with 200 μ M of the corresponding nucleotide. For reactions with short peptide substrates ( Fig. 1g ), 0.01% Triton X-100 (Sigma) was added to reduce non-specific interaction of peptides with the test tube. Reactions with peptide substrates were resolved on 16% or 19% tricine-urea SDS-PAGE gels 53 . The K i values of PRAS40 fragments inhibiting S6K1 367-404 phosphorylation shown in Fig. 3a were calculated using the IC 50 values, the 10 μ M S6K1 367-404 substrate concentration, and the 430 μ M K m of this substrate peptide (Extended Data Fig. 1b ) according to the competitive inhibitor equation K i = IC 50 /(1 + ([S]/K m )). In vivo S6K1 phosphorylation assay. HA-S6K1 ki wild type and mutants were cloned into the pcDNA3.1(+ ) vector. HEK293F cells (Invitrogen) were maintained in DMEM medium with 10% fetal bovine serum (Sigma) at 37 °C and 5% CO 2 . For transfection, cells were seeded into six-well tissue culture plates, cultured to 70% confluence, and exchanged into fresh medium 1 h before transfection. Cells were transfected with 2 μ g each of HA-S6K1 ki wild-type or mutant plasmids using Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells were lysed in 50 mM Tris-HCl, 150 mM NaCl, 0.5 mM TCEP, 1% Triton-X100, 2 mM EDTA, 50 mM NaF, 10 mM β -glycerolphosphate, and 10 mM Na-pyrophosphate, pH 7.5, and one tablet each of cOmplete protease inhibitor and PhosSTOP cocktail (Roche). Whole-cell extracts were adjusted to 2 mg ml −1 with lysis buffer and NuPAGE LDS sample loading buffer (Invitrogen), and boiled for 5 min. Twenty micrograms of whole-cell extract were loaded on gel for immunoblotting with anti-HA antibody (Santa Cruz, SC805) or anti-phospho-S6K1 (T389) antibody (Cell Signaling, 9205). The immunoblots were quantified by normalizing the antiphospho-S6K1 signal to the anti-HA signal of each reaction. ATPase assay. The ATP hydrolysis assays were set up similarly as the in vitro kinase assays, except without mTOR substrates. To vary the final ATP concentrations, cold ATP was serially diluted and supplemented with [γ -32 P]ATP (4 μ Ci per reaction). The reaction was initiated by mixing the ATP with the enzyme (10 μ l total volume), Article reSeArcH incubated for 20 min at 30 °C, and stopped by adding 10 μ l of 2 M formic acid. Two microlitres of each reaction were then spotted on a PEI Cellulose TLC plate (Millipore), developed in 1 M formic acid and 0.5 M LiCl, dried, and quantified by phosphorimaging. Fluorescence polarization. FITC (fluorescein isothiocyanate)-labelled TOS peptides were purchased from Peptide 2.0. Peptides were quantified by absorption at 495 nm by more than 20-fold dilution in 10 mM Tris-HCl, pH 8.0, using an extinction coefficient of 75,000 cm −1 M −1 . A series of 60-μ l binding conditions using serially diluted protein with 20 nM FITC-labelled TOS peptides was set up in buffer consisting of 10 mM Tris-HCl, 100 mM NaCl, 2.5% glycerol, and 1 mM TCEP, pH 8.0. Each binding condition was set up in triplicate and equilibrated at room temperature for 15 min. The fluorescence anisotropy measurements were taken with a Cary Eclipse Fluorescence Spectrophotometer with automated polarization accessory (Agilent Technologies), using 485-nm excitation (5-nm slit) and 512-nm emission (10 nm slit) wavelengths, and a G factor of 1.5111. The apparent dissociation constants (K d ) were obtained by fitting the data to a one-site binding model, by minimizing the sum of the square of the differences. Data availability. The cryo-EM maps, including the three focused reconstruction maps and the structure factors of their composite map used in model refinement, and the refined atomic models have been deposited in the Electron Microscopy Data Bank (EMDB) and the Protein Data Bank (PDB), under accession numbers EMDB-7087 and PDB 6BCX for apo-mTORC1, and EMDB-7086 and PDB 6BCU for RHEB-mTORC1. The coordinates and structure factors of the FRB-S6K1 complex (5WBH), atRaptor (5WBI), atRaptor-4EBP1 TOS (5WBJ), atRaptor-S6K1 TOS (5WBK), atRaptor-PRAS40 TOS (5WBL), mTOR ΔN -mLST8-PRAS40 173-256 (5WBU), and mTOR ΔN -mLST8-PRAS40 114-207 (5WBY) have been deposited in the Protein Data Bank. All other data are available from the corresponding author upon reasonable request.
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Extended Data Figure 1 | Substrate recruitment by the FRB domain. a, Deletion mapping of S6K1 FRB-binding motif polypeptides (2 μ M) using phosphorylation by the mTOR ΔN -mLST8 (30 nM) as the assay, extending previous findings 23 . Truncation up to 7 residues N-terminal to the Thr389 phosphorylation site (indicated by asterisk) has minimal effect, whereas C-terminal truncations starting 15 residues from Thr389 successively reduce phosphorylation. The polypeptides were produced as described in Methods for the S6K1 367-404 peptide. Column graph shows velocity divided by enzyme concentration from the quantification of the 32 P autoradiogram. Columns show means and markers show values from independent experiments (n = 6 for 382-410, 367-392, 367-398, and 367-410 reactions, n = 5 for 382-402, n = 4 for 367-404, and n = 3 for 367-402). The column labelled f.l. S6K1 shows the phosphorylation level of full-length S6K1 ki (ki superscript indicates the kinase-inactive K100R mutant) under the same conditions, as reported in ref. 23 . Truncation of the S6K1 peptide to 20 residues (S6K1 382-402 ), which is the standardized length used in the peptide library of Fig. 1g , reduces phosphorylation to approximately 20% of S6K1 367-404 , probably in part because of endeffects destabilizing the helix as well as eliminating some minor contacts. b, Michaelis-Menten steady-state kinetic constants for mTOR ΔN -mLST8 (30 nM) phosphorylating wild-type and the indicated mutant S6K1 367-404 peptides, quantified as in a. Graph shows means (dashes) and values (markers as indicated) from independent experiments (n = 3, except for the 1, 2, 10, 750, 900, and 1,200 μ M points, which are n = 2). Also shown are the K m and k cat values, calculated by nonlinear regression fitting of the data, above the graph, and their simulated curves in the graph. Mutations that significantly reduce phosphorylation but do not make substantial direct FRB contacts include S394A, which eliminates a hydrogen bond that stabilizes the helix N terminus, and the helix-breaking V395G mutation, which further reduces phosphorylation compared with V395A ( Fig. 1d) ; together, these point to the importance of the helical conformation. Additional mutations include Val391 and Pro393, in the segment between Thr389 and the start of the helix. Pro393 may be important for guiding the FRB-anchored substrate to the kinase active site, and that the P + 2 residue Val391 may be involved in contacts to the kinase C-lobe, where, by analogy with canonical kinases, the peptide segment of the phosphorylation site and its immediate vicinity are expected to bind. c, Superposition of the FRB-S6K1 interface onto the FRB-rapamycin-FKBP12 structure 25 (FKBP12 is omitted for clarity), highlighting the similarities in the binding of the Leu396 side chain to the same pocket as rapamycin's key C23 methyl group and the flanking portions of its triene arm. The FRB-S6K1 interface is coloured as in Fig. 1b ; rapamycin is green and its associated FRB domain is cyan. In the crystals of the FRB-S6K1 389-414 fusion protein, S6K1 residues 389-391 and 411-414 are disordered, while residues 405-410 are involved in crystal packing. d, Quantification of the reactions shown in Fig. 1h . e, X-ray data collection and refinement statistics for the FRB 2018-2114 -S6K1α II 389-414 fusion protein structure.
Extended Data Figure 2 | RAPTOR-4EBP1 TOS interface and density in the cryo-EM structure of mTORC1. a, Human RAPTOR-4EBP1 TOS interface from the 3.0 Å refined human mTORC1 cryo-EM structure, coloured as in Fig. 2b . Only the RAPTOR side chains that make hydrogen bonds (red dotted lines) or electrostatic or van der Waals contacts to 4EBP1 are shown. b, Stereo view of the cryo-EM density of the human RAPTOR-4EBP1 TOS interface. Although the complex contained fulllength 4EBP1, only an eight-residue segment is ordered in the cryo-EM reconstruction (also see Extended Data Fig. 7a ). c, Cryo-EM data collection and refinement statistics.
Extended Data Figure 3 | atRaptor-TOS motif crystal structures and human RAPTOR-TOS motif dissociation constants. a, Stereo view of the mF o − dF c electron density of the atRaptor-4EBP1 99-118 co-crystals, calculated with phases from atRaptor before any 4EBP1 was built into the model. The structure is coloured as in Fig. 2b , and the map, calculated at 3.0 Å and contoured at 2.2σ, is shown as blue mesh. Of 20 residues in the 4EBP1 peptide in the crystals, only the 8-residue segment shown is ordered. b, Stereo view of the mF o − dF c electron density, calculated as in a, of the atRaptor-S6K1 1-14 co-crystals. The 3.1 Å map is contoured at 2.2σ. As with the 4EBP1 co-crystals, only 8 of the 14 S6K1 residues are ordered. c, Stereo view of the mF o − dF c electron density, calculated as in a, of the atRaptor-PRAS40 124-139 co-crystals. The 3.35 Å map is contoured at 1.9σ. Only 8 of the 16 PRAS40 residues are ordered. In addition, side chain of Glu133 has poor density and is only tentatively built. d, Molecular surface representation of the atRaptor-TOS-binding groove, coloured according to the electrostatic potential (−6kT to + 6kT) calculated without the 4EBP1 peptide (shown as sticks) using APBS 54 and illustrated with PyMOL. The TOS-binding groove has an overall basic electrostatic potential due to five arginine and one lysine residues, explaining the tendency of acidic residues to be present at the non-conserved and flanking positions of the TOS motif. e, Binding of the indicated human 4EBP1 TOS mutant peptides (mutation in red) to human RAPTOR measured by fluorescence polarization anisotropy. Graph shows means as dashes and values from three independent experiments with the indicated markers and colours. Dissociation constants from the nonlinear regression fitting of the data are also shown, and simulated binding curves are overlaid on the data. f, Binding of the TOS motif peptides of human 4EBP1 (blue), S6K1 (red), and PRAS40 (green) to human RAPTOR measured by fluorescence polarization anisotropy. Graph shows means as dashes and values from three independent experiments with the indicated markers and colours. Also shown are the dissociation constants from the nonlinear regression fitting of the data and the simulated binding curves.
Extended Data Figure 7 | Apo-mTORC1 cryo-EM density, interfaces, and conformational flexibility. a, The 4EBP1 amphipathic helix density on the FRB does not have interpretable cryo-EM density. The map shown is of a 3D class (~ 30% of particles) with the highest relative level of density; the FRB side chains that contact the S6K1 substrate in Fig. 1c are shown as red sticks to map the site, the rest of mTOR is coloured as in Fig. 4a , and AMPPNP is in space-filling representation. Unlike the 4EBP1 TOS, which has a level of density comparable to that of its binding site (Extended Data Fig. 2b) , the putative density of the 4EBP1 amphipathic helix is much weaker than that of the FRB, suggestive of partial occupancy. We presume this is due, in part, to our cryo-EM samples containing 260 mM NaCl, which substantially reduces 4EBP1 phosphorylation and thus probably further weakens substrate-FRB association (right). b, Stereo view of the 3.0 Å cryo-EM density of the consensus apo-mTORC1 reconstruction, showing mTOR N-heat (residues approximately 650-850 shown in stick representation coloured green, red, and blue for C, O, and N atoms, respectively). c, Stereo view of the 3.0 Å cryo-EM density of the consensus apo-mTORC1 reconstruction showing mTOR M-heat (residues approximately 960-1105 shown in stick representation coloured sand, red, and blue for C, O, and N atoms, respectively). d, The end of the N-heat solenoid (residues 848-898; green) is anchored on the middle of the FAT domain (residues 1565-1627; light cyan). Close-up view showing side chains (glycine C α atoms as spheres) and backbone groups (blue spheres for amide and sticks for carbonyl groups) involved in intra-molecular van der Waals or hydrogen bonds (yellow dotted lines). For clarity, only N-heat residues 836-903 and FAT residues 1537-1664 are shown. e, The mTOR binding elements of RAPTOR (purple) are encompassed within its conserved RNC (raptor N-terminal conserved) 7 , with the caspase domain contacting M-heat of one mTOR protomer (sand), the caspase insertion contacting both M-heat and the N-heat (green) of the other mTOR protomer, and the first three armadillo repeats of its solenoid contacting N-heat. Side chains are shown as in d. Hydrogen bond contacts are shown as red dotted lines. N-heat and M-heat structural elements above the plane of the figure are omitted for clarity. f, The conformational flexibility of apo-mTORC1 is associated with bending at a major hinge region of three heat repeats (indicated by a box) in the N-heat solenoid, in between its FAT and RAPTOR-M-heat interacting segments. Figure shows C α trace of the tripartite interface between N-heat of protomer 2, M-heat of protomer 1, and RAPTOR of the four apo-mTORC1 3D classes of Extended Data Fig. 5c (coloured as in Fig. 4a ) and RHEB-mTORC1 (all red). The four apo-mTORC1 classes were refined to 4.5 Å or better, and together with RHEB-mTORC1 were superimposed on RAPTOR (residues 52-422). Figure also highlights the flexibility on the N-terminal half of the N-heat solenoid in apo-mTORC1 (see Supplementary Discussion) .
